PMID- 30348127 OWN - NLM STAT- MEDLINE DCOM- 20190129 LR - 20190129 IS - 1471-2407 (Electronic) IS - 1471-2407 (Linking) VI - 18 IP - 1 DP - 2018 Oct 22 TI - Age-related microRNAs in older breast cancer patients: biomarker potential and evolution during adjuvant chemotherapy. PG - 1014 LID - 10.1186/s12885-018-4920-6 [doi] LID - 1014 AB - BACKGROUND: MicroRNAs (miRNAs) are important regulators of cellular function and have been associated with both aging and cancer, but the impact of chemotherapy on age-related miRNAs has barely been studied. Our aim was to examine whether chemotherapy accelerates the aging process in elderly breast cancer patients using miRNA expression profiling. METHODS: We monitored age-related miRNAs in blood of women, aged 70 or older, receiving adjuvant chemotherapy (docetaxel and cyclophosphamide, TC) for invasive breast cancer (chemo group, CTG, n = 46). A control group of older breast cancer patients without chemotherapy was included for comparison (control group, CG, n = 43). All patients underwent geriatric assessment at inclusion (T0), after 3 months (T1) and 1 year (T2). Moreover, we analysed the serum expression of nine age-related miRNAs (miR-20a, miR-30b, miR-34a, miR-106b, miR-191, miR-301a, miR-320b, miR-374a, miR-378a) at each timepoint. RESULTS: Except for miR-106b, which behaved slightly different in CTG compared to CG, all miRNAs showed moderate fluctuations during the study course with no significant differences between groups. Several age-related miRNAs correlated with clinical frailty (miR-106b, miR-191, miR-301a, miR-320b, miR-374a), as well as with other biomarkers of aging, particularly Interleukin-6 (IL-6) and Monocyte Chemoattractant Protein-1 (MCP-1) (miR-106b, miR-301a, miR-374a-5p, miR-378a-3p). Moreover, based on their 'aging miRNA' profiles, patients clustered into two distinct groups exhibiting significantly different results for several biological/clinical aging parameters. CONCLUSIONS: These results further corroborate our earlier report, stating that adjuvant TC chemotherapy does not significantly boost aging progression in elderly breast cancer patients. Our findings also endorsed specific age-related miRNAs as promising aging/frailty biomarkers in oncogeriatric populations. TRIAL REGISTRATION: ClinicalTrials.gov, NCT00849758 . Registered on 20 February 2009. This clinical trial was registered prospectively. FAU - Dalmasso, Bruna AU - Dalmasso B AUID- ORCID: 0000-0002-1534-0521 AD - Department of Oncology, Laboratory of Experimental Oncology (LEO), Leuven, KU, Belgium. brunasamia.dalmasso@dimi.unige.it. AD - Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium. brunasamia.dalmasso@dimi.unige.it. AD - Genetics of Rare Cancers, Department of Internal Medicine and Medical Specialties, University of Genoa, Genoa, Italy. brunasamia.dalmasso@dimi.unige.it. FAU - Hatse, Sigrid AU - Hatse S AD - Department of Oncology, Laboratory of Experimental Oncology (LEO), Leuven, KU, Belgium. AD - Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium. FAU - Brouwers, Barbara AU - Brouwers B AD - Department of Oncology, Laboratory of Experimental Oncology (LEO), Leuven, KU, Belgium. AD - Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium. FAU - Laenen, Annouschka AU - Laenen A AD - Interuniversity Centre for Biostatistics and Statistical Bioinformatics, Leuven, Belgium. FAU - Berben, Lieze AU - Berben L AD - Department of Oncology, Laboratory of Experimental Oncology (LEO), Leuven, KU, Belgium. AD - Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium. FAU - Kenis, Cindy AU - Kenis C AD - Department of General Medical Oncology and Geriatric Medicine, University Hospitals Leuven, Leuven, Belgium. FAU - Smeets, Ann AU - Smeets A AD - Multidisciplinary Breast Center, University Hospitals Leuven, Leuven, Belgium. FAU - Neven, Patrick AU - Neven P AD - Multidisciplinary Breast Center, University Hospitals Leuven, Leuven, Belgium. FAU - Schoffski, Patrick AU - Schoffski P AD - Department of Oncology, Laboratory of Experimental Oncology (LEO), Leuven, KU, Belgium. AD - Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium. FAU - Wildiers, Hans AU - Wildiers H AD - Department of Oncology, Laboratory of Experimental Oncology (LEO), Leuven, KU, Belgium. AD - Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium. LA - eng SI - ClinicalTrials.gov/NCT00849758 PT - Journal Article DEP - 20181022 PL - England TA - BMC Cancer JT - BMC cancer JID - 100967800 RN - 0 (Biomarkers, Tumor) RN - 0 (MicroRNAs) SB - IM MH - Age Factors MH - Aged MH - Aged, 80 and over MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use MH - Biomarkers, Tumor MH - Breast Neoplasms/drug therapy/*genetics/pathology MH - Chemotherapy, Adjuvant MH - Evolution, Molecular MH - Female MH - Gene Expression Profiling MH - *Gene Expression Regulation, Neoplastic MH - Geriatric Assessment MH - Humans MH - MicroRNAs/*genetics MH - Quality of Life MH - Transcriptome PMC - PMC6196565 OTO - NOTNLM OT - Adjuvant chemotherapy OT - Aging OT - Biomarkers OT - Breast cancer OT - Elderly OT - Oncogeriatrics OT - microRNA COIS- ETHICS APPROVAL AND CONSENT TO PARTICIPATE: The study was approved by the local ethics committees of Clinique Sainte Elisabeth (Namur), Imelda Hospital (Bonheiden), Jessa Hospital (Hasselt), Zol Ziekenhuis Oost-Limburg (Genk), Jules Bordet Institute (Brussels). Final approval was given by the University Hospitals Leuven central ethics committee on 20 April 2009. All patients signed a written informed consent in accordance to the Helsinki Declaration. CONSENT FOR PUBLICATION: Not applicable. COMPETING INTERESTS: The authors declare that they have no competing interests. PUBLISHER'S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. EDAT- 2018/10/24 06:00 MHDA- 2019/01/30 06:00 PMCR- 2018/10/22 CRDT- 2018/10/24 06:00 PHST- 2017/12/15 00:00 [received] PHST- 2018/10/09 00:00 [accepted] PHST- 2018/10/24 06:00 [entrez] PHST- 2018/10/24 06:00 [pubmed] PHST- 2019/01/30 06:00 [medline] PHST- 2018/10/22 00:00 [pmc-release] AID - 10.1186/s12885-018-4920-6 [pii] AID - 4920 [pii] AID - 10.1186/s12885-018-4920-6 [doi] PST - epublish SO - BMC Cancer. 2018 Oct 22;18(1):1014. doi: 10.1186/s12885-018-4920-6.